Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors

Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors

Item
http://www.wikidata.org/entity/Q28478344
Activated RET and ROS: two new driver mutations in lung adenocarcinoma.YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer.Selective use of vandetanib in the treatment of thyroid cancer.Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.Expression of caveolin-1 is correlated with lung adenocarcinoma proliferation, migration, and invasion.The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells.Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.Sunitinib reverse multidrug resistance in gastric cancer cells by modulating Stat3 and inhibiting P-gp function.Valproic acid, an inhibitor of class I histone deacetylases, reverses acquired Erlotinib-resistance of lung adenocarcinoma cells: a Connectivity Mapping analysis and an experimental study.Targeted Therapy for Medullary Thyroid Cancer: A Review.Bromelain has significant clinical benefits after extraction of the third molar during chemotherapy in patients with hematologic tumor.Caveolin-1 Inhibits Proliferation, Migration, and Invasion of Human Colorectal Cancer Cells by Suppressing Phosphorylation of Epidermal Growth Factor Receptor.Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study.
P2860

Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors

Item
http://www.wikidata.org/entity/Q28478344
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antitumor activity of sorafeni ...... GFR tyrosine kinase inhibitors
@ast
Antitumor activity of sorafeni ...... GFR tyrosine kinase inhibitors
@en
Antitumor activity of sorafeni ...... GFR tyrosine kinase inhibitors
@nl
type
label
Antitumor activity of sorafeni ...... GFR tyrosine kinase inhibitors
@ast
Antitumor activity of sorafeni ...... GFR tyrosine kinase inhibitors
@en
Antitumor activity of sorafeni ...... GFR tyrosine kinase inhibitors
@nl
prefLabel
Antitumor activity of sorafeni ...... GFR tyrosine kinase inhibitors
@ast
Antitumor activity of sorafeni ...... GFR tyrosine kinase inhibitors
@en
Antitumor activity of sorafeni ...... GFR tyrosine kinase inhibitors
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Antitumor activity of sorafeni ...... GFR tyrosine kinase inhibitors
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0028841
P407
P433
P478
P50
P577
P5875
P698
P932